Royalty Pharma Plc Stock Price, News & Analysis

Royalty Pharma plc (Nasdaq: RPRX) has announced its dividend for the third quarter of 2024. The company's board of directors has approved a payment of $0.21 per Class A ordinary share. This dividend will be distributed on September 13, 2024, to shareholders who are on record as of the close of business on August 16, 2024. This announcement provides investors with information about the company's ongoing commitment to returning value to shareholders through regular dividend payments.

Royalty Pharma (Nasdaq: RPRX) announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024. The company will engage in a fireside chat scheduled for 2:00 p.m. ET. The event will be webcast live and later archived for at least thirty days, accessible through Royalty Pharma's Events page.

Royalty Pharma (Nasdaq: RPRX) announced the pricing of $1.5 billion in senior unsecured notes.

The offering includes $500 million of 5.150% Notes due 2029, $500 million of 5.400% Notes due 2034, and $500 million of 5.900% Notes due 2054. These notes will be guaranteed by Royalty Pharma Holdings.

The transaction is expected to close on June 10, 2024. Proceeds will be used for general corporate purposes.

Major financial institutions such as BofA Securities, Citigroup, and J.P. Morgan are among the joint lead book-running managers.

Royalty Pharma announced a $905 million agreement with Agios Pharmaceuticals to acquire future royalties on Servier’s vorasidenib, contingent on FDA approval. Vorasidenib, a targeted therapy for IDH-mutant glioma, has shown unprecedented efficacy and tolerability in Phase 3 trials and received priority review with a PDUFA date of August 20, 2024.

The drug is projected to achieve over $1 billion in annual peak sales in the U.S., potentially generating more than $150 million in annual royalties for Royalty Pharma. If approved, royalties may continue through 2038.

An investor call is scheduled for today, May 28, to discuss the deal.

Royalty Pharma and Cytokinetics announced an expanded strategic funding collaboration worth up to $575 million to support the commercialization of aficamten and advance Cytokinetics' cardiovascular R&D pipeline. The deal includes immediate $250 million funding and additional funding options tied to clinical and regulatory milestones. Key elements are commercial launch funding, royalty restructuring, development funding for clinical trials, and equity purchase by Royalty Pharma. This collaboration aims to fortify Cytokinetics' capital structure and help the company achieve its strategic goals in cardiology.

Royalty Pharma plc (Nasdaq: RPRX) will be presenting at upcoming investor conferences, including the RBC Capital Markets 2024 Global Healthcare Conference and BofA Securities 2024 Healthcare Conference in May. The webcasts will be available on Royalty Pharma's website for at least thirty days.

Royalty Pharma plc (Nasdaq: RPRX) reported 14% growth in Royalty Receipts driving Portfolio Receipts of $717 million for the first quarter of 2024. Full year 2024 guidance confirmed at $2,600 to $2,700 million with a commitment to grow dividends annually. The company's development-stage portfolio has expanded significantly, with key events expected in the coming year. Financial capacity of over $3.5 billion to execute transactions, despite a decline in Portfolio Receipts due to a high base of comparison. Strong Royalty Receipts growth and a focus on new royalty opportunities demonstrate a robust business strategy.

Royalty Pharma plc (Nasdaq: RPRX) announced the acquisition of royalties and milestones on frexalimab from ImmuNext, Inc. for approximately $525 million. Frexalimab, developed by Sanofi, is a promising therapy for multiple sclerosis with blockbuster potential in various immune-mediated diseases. This acquisition expands Royalty Pharma's development-stage portfolio to 15 therapies, estimating to generate over $1 billion in peak royalties annually.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) received a $50 million milestone payment from Royalty Pharma plc for completing enrollment in the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen. Arrowhead stands to earn up to an additional $375 million from Amgen and $110 million from Royalty Pharma in milestone payments related to olpasiran. The rapid enrollment in the trial reflects the interest in olpasiran, developed using Arrowhead's TRiMTM technology. With three Phase 3 programs in progress, including plozasiran, Arrowhead continues to advance RNA interference therapies.